Chemistry:Azasetron

Short description: Chemical compound

Azasetron

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	none
Pharmacokinetic data
Bioavailability	90%
Excretion	60-70%
Identifiers
IUPAC name N-(1-azabicyclo[2.2.2]octan-8-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide
CAS Number	123040-69-7
PubChem CID	2264
IUPHAR/BPS	2285
ChemSpider	2177 Y
UNII	77HC7URR9Z
KEGG	D07481 Y
ChEMBL	ChEMBL1598608
Chemical and physical data
Formula	C17H20ClN3O3
Molar mass	349.82 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1C(=O)COc2c1cc(Cl)cc2C(=O)NC3CN4CCC3CC4
InChI InChI=1S/C17H20ClN3O3/c1-20-14-7-11(18)6-12(16(14)24-9-15(20)22)17(23)19-13-8-21-4-2-10(13)3-5-21/h6-7,10,13H,2-5,8-9H2,1H3,(H,19,23) Y Key:WUKZPHOXUVCQOR-UHFFFAOYSA-N Y
(verify)

Azasetron is an antiemetic which acts as a 5-HT₃ receptor antagonist, pK_i = 9.27 It is used in the management of nausea and vomiting induced by cancer chemotherapy (such as cisplatin chemotherapy). Azasetron hydrochloride is given in a usual dose of 10 mg once daily by mouth or intravenously. It is approved for marketing in Japan, and marketed exclusively by Torii Pharmaceutical Co., Ltd. under the trade names "Serotone I.V. Injection 10 mg" and "Serotone Tablets 10 mg". Pharmacokinetics data from S. Tsukagoshi.

R-azasetron besylate (SENS-401) has been studied to prevent hearing loss related to sudden sensorineural hearing loss (SSNHL), acoustic trauma, and cisplatin-induced ototoxicity.